The estimated Net Worth of Peter Greenleaf is at least $12.7 Million dollars as of 6 March 2024. Mr. Greenleaf owns over 126,981 units of Aurinia Pharmaceuticals Inc stock worth over $9,939,404 and over the last 9 years he sold AUPH stock worth over $1,112,785. In addition, he makes $1,678,600 as President, Chief Executive Officer, and Director at Aurinia Pharmaceuticals Inc.
Sign up
Mr. Greenleaf AUPH stock SEC Form 4 insiders trading
Peter has made over 11 trades of the Aurinia Pharmaceuticals Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 126,981 units of AUPH stock worth $711,094 on 6 March 2024.
The largest trade he's ever made was exercising 200,000 units of Aurinia Pharmaceuticals Inc stock on 28 November 2016 worth over $1,350,000. On average, Peter trades about 12,286 units every 66 days since 2016. As of 6 March 2024 he still owns at least 1,522,114 units of Aurinia Pharmaceuticals Inc stock.
You can see the complete history of Mr. Greenleaf stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Peter Greenleaf biography
Peter S. Greenleaf serves as President, Chief Executive Officer, Director of the Company. Mr. Peter Greenleaf currently serves as the President, Chief Executive Officer and member of the Board since April 29, 2019. Prior to this, Mr. Greenleaf served as the Chief Executive Officer and a member of the board of directors of Cerecor, Inc. (NASDAQ: CERC). From March 2014 to February 2018, Mr. Greenleaf served as CEO and Chairman of Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP), a company that focused on the development and commercialization of medicines to meet major unmet medical needs of patients worldwide until it was sold in February 2018 to U.K. pharmaceutical giant Mallincrodt plc. Mr. Greenleaf also served as Chief Executive Officer and a member of the board of directors of Histogenics Corporation, a regenerative medicine company. From 2006 to 2013, Mr. Greenleaf was employed by Medlmmune LLC, the global biologics arm of AstraZeneca, where he most recently served as President. From January 2010 to June 2013, Mr. Greenleaf also served as President of Medlmmune Ventures, a wholly owned venture capital fund within the AstraZeneca Group. Prior to serving as President of Medlmmune, Mr. Greenleaf was Senior Vice President, Commercial Operations of MedImmune, responsible for its commercial, corporate development and strategy functions. Mr. Greenleaf has also held senior commercial roles at Centocor, Inc. (now Janssen Biotechnology, Johnson & Johnson) from 1998 to 2006, and at Boehringer Mannheim (now Roche Holdings) from 1996 to 1998. Mr. Greenleaf currently chairs the Maryland Venture Fund Authority. He is also currently a member of the board of directors of Antares Pharmaceuticals, Inc (NASDAQ: ATRS), and is the Chairman of the board of directors of BioDelivery Sciences International, Inc (NASDAQ: BDSI). Mr. Greenleaf earned an MBA degree from St. Joseph’s University and a BS degree from Western Connecticut State University.
What is the salary of Peter Greenleaf?
As the President, Chief Executive Officer, and Director of Aurinia Pharmaceuticals Inc, the total compensation of Peter Greenleaf at Aurinia Pharmaceuticals Inc is $1,678,600. There are no executives at Aurinia Pharmaceuticals Inc getting paid more.
How old is Peter Greenleaf?
Peter Greenleaf is 50, he's been the President, Chief Executive Officer, and Director of Aurinia Pharmaceuticals Inc since 2019. There are 12 older and 3 younger executives at Aurinia Pharmaceuticals Inc. The oldest executive at Aurinia Pharmaceuticals Inc is George Milne, 76, who is the Independent Chairman of the Board.
What's Peter Greenleaf's mailing address?
Peter's mailing address filed with the SEC is #140, 14315-118 AVENUE, , EDMONTON, A0, T5L 4S6.
Insiders trading at Aurinia Pharmaceuticals Inc
Over the last 4 years, insiders at Aurinia Pharmaceuticals Inc have traded over $22,019,765 worth of Aurinia Pharmaceuticals Inc stock and bought 107,125 units worth $893,295 . The most active insiders traders include Timothy P Walbert, Michael R Hayden, and Michael Robert Martin. On average, Aurinia Pharmaceuticals Inc executives and independent directors trade stock every 18 days with the average trade being worth of $193,451. The most recent stock trade was executed by Scott Michael Habig on 6 August 2024, trading 18,249 units of AUPH stock currently worth $96,902.
What does Aurinia Pharmaceuticals Inc do?
aurinia pharmaceuticals is a biotechnology company located in 5120-75 street, edmonton, canada.
What does Aurinia Pharmaceuticals Inc's logo look like?
Complete history of Mr. Greenleaf stock trades at Antares Pharma Inc, Aurinia Pharmaceuticals Inc, Biodelivery Sciences International, Cerecor Inc, and AB Active ETFs Inc
Aurinia Pharmaceuticals Inc executives and stock owners
Aurinia Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Peter Greenleaf,
President, Chief Executive Officer, Director -
Peter S. Greenleaf M.B.A.,
Pres, CEO & Director -
Maxwell Donley,
Executive Vice President, Internal Operations & Strategy -
Neil Solomons,
Chief Marketing Officer -
Massimiliano Colao,
Chief Commercial Officer -
Robert Huizinga,
Executive Vice President - Corporate Development -
Matthew Maxwell Donley M.B.A.,
Exec. VP of Operations & Strategy -
Joseph M. Miller CPA,
Chief Financial Officer -
Dennis Bourgeault,
Chief Financial Officer -
Michael Martin,
Chief Operating Officer -
Daniel Billen,
Director -
George Milne,
Independent Chairman of the Board -
Michael Hayden,
Independent Director -
Stephen P. Robertson,
Exec. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer -
Joseph Hagan,
Independent Director -
David Jayne,
Independent Director -
R. Hector MacKay-Dunn,
Director -
Jill Leversage,
Independent Director -
Stephen Robertson,
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary -
Timothy Walbert,
Independent Director -
Max Colao,
Chief Commercial Officer -
Tim Hermes,
Vice President of Market Access -
Cara Felish,
Vice President of Commercial Operations -
Chris Hays,
Vice President of Marketing -
Fran Lynch,
Vice President of Sales -
Glenn Schulman,
Senior Vice President - Corporate Communications and Investor Relations -
Michael R. Martin,
Chief Bus. Officer -
Dr. Robert B. Huizinga M.Sc., Ph.D., R.N., RN NNC, MSc(Epi), CNeph(C),
Exec. VP of Research -
Scott Michael Habig,
Chief Commercial Officer -
Volker Knappertz,
EVP, Research and Development -
Joseph M Miller,
Chief Financial Officer -
Brinda Balakrishnan,
Director -
Robert T Foster,
Director -
Massimilano Colao,
Chief Commercial Officer -
Jeffrey Allen Bailey,
Director -
Karen L. Smith,
Director